Opendata, web and dolomites


Innovative Laser and Fiber System for Non-Toxic, Efficient and Cost-Effective Treatment of Cancer

Total Cost €


EC-Contrib. €






Project "LUMAX" data sheet

The following table provides information about the project.


Organization address
city: HALLE
postcode: 6120
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LAB-ON-FIBER GMBH DE (HALLE) coordinator 50˙000.00


 Project objective

'Our aim with this proposal is to bring the desired technology for a non-toxic, efficient and cost-effective cancer treatment. Basically, all cytotoxic drugs (chemotherapy) and radiation lead to apoptosis, the programmed cell death of tumor cells. These techniques on the other hand have well documented side effects like losing hair, teeth, damaged quality of life effecting lives of more than 14M cancer patients and their families worldwide. LoF revolutionizes 'non-toxic' cancer treatment with her innovative laser probes and systems serving oncologists tasked with saving lives by developing and applying the most effective therapies. Our state-of-the-art laser probes and systems form a feedback loop and enable oncologists for the “first time” to monitor absorbed dose to the tissue in real time which is decisive for the treatment efficacy. Cancer cost the EU €126 billion in 2013, with health care accounting for €51 billion (40% of the total cost) for post-treatments. EU needs better, effective solutions to drive costs down. With our solution which is the subject of this proposal we offer a potential cost-saving of 60%. The market potential for the envisaged the clinical applications is based on current cases at around 2.24 billion euros worldwide. Our innovation opens the door to new treatment applications and could be used to treat up to 5 million people per year from 2022.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LUMAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LUMAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

EDITUS (2019)

Helping our customers to design smart and safe tomorrows’ communication systems

Read More  

Presque (2019)

Smart Nursing Bra

Read More